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Abstract
Insulin is known to regulate multiple cellular functions and is used for the treatment of diabetes. MicroRNAs have been
demonstrated to be involved in many human diseases, including Type 2 diabetes. In this study, we showed that insulin
decreased miR-99a expression levels, but induced glucose consumption and lactate production, and increased the
expression of mTOR, HIF-1a and PKM2 in HepG2 and HL7702 cells. Forced expression of miR-99a or rapamycin treatment
blocked insulin-induced PKM2 and HIF-1a expression, and glucose consumption and lactate production. Meanwhile,
knockdown of HIF-1a inhibited PKM2 expression and insulin-induced glucose consumption. Taken together, these findings
will reveal the role and mechanism ofinsulin in regulating glycolytic activities via miR-99a/mTOR.
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Introduction
Insulin, secreted from pancreatic B-cells, is an important
peptide hormone and usually used for the treatment of diabetes
[1,2]. Insulin is known to regulate multiple cellular functions such
as synthesis of sugar, fat and protein, and is central in regulating
carbohydrate and fat metabolism [3,4]. MicroRNAs (miRNAs) are
small non-coding RNAs with 19–22 bp length and post-transcrip-
tionally regulate gene expression by binding to 39-untranslated
regions (39-UTRs) of target mRNAs [5,6]. MiRNAs have been
demonstrated to be involved in many human diseases [5,6,7],
including type 2 diabetes [8,9,10]. Many studies showed that
miRNAs can regulate insulin secretion. For example, miR-33a
decreased glucose-stimulated insulin secretion via reducing
expression of ABCA1(ATP-binding cassette transporter A1) [11].
Over-expression of miR-375 reduced glucose-induced insulin
secretion by regulating myotrophin (Mtpn) [12]. Recent studies
found that the expression of miRNAs can be regulated by insulin
such as miR-208 which played a role in insulin-induced VSMC
proliferation by p21, a key member of CDK-inhibitory protein
family [13]. However, little is known about the roles of miRNAs in
insulin-regulated cellular functions.
Mammalian target of rapamycin (mTOR) is a serine/threonine
kinase which plays critical roles in regulating protein synthesis,
ribosomal protein translation, cap-dependent translation and
mTOR signaling is associated with cell growth, proliferation,
apoptosis [14,15,16]. Emerging evidence demonstrates that
mTOR are regulated by miRNAs. Through mTOR pathway,
miR-204 regulated cancer cell migration and invasion [17], and
miR-100 induced cell-cycle arrest to suppress cell proliferation and
motility in bladder cancer cells [18]. These results are consistent
with our observation that mTOR was inhibited by miR-99a in
hepatocellular carcinoma cells (HCC). It has been demonstrated
that insulin can regulate glucose metabolism by activating mTOR
pathway [19,20]. The liver is known to be important in regulating
glucose metabolism in response to growth factors and insulin
treatment [21,22]. With the co-treatment of saffron and insulin,
mTOR pathway improves the insulin sensitivity [23]. mTOR
pathway is required to sustain glucose metabolism and glycolysis,
and is important in the transcriptional program of glucose
transporters and multiple rate-limiting glycolytic enzymes [24].
Pyruvate kinase M2 (PKM2), which is expressed in fetal tissues,
plays a critical role in glycolytic pathway as a rate-limiting enzyme,
and catalyzes the dephosphorylation of phosphoenolpyruvate
topyruvate [25,26]. Expression levels of PKM2 are upregulated
in human cancer cells [27,28], PKM2 promotes glucose metab-
olism in cancer cells by stimulating transactivation of glycolytic
genes [25,29]. However, itremains to be defined how PKM2 is
regulated in cells. PKM2 emerges as an important regulator in
glucose metabolism during cancer development and tumor growth
[30,31,32]. Recent studies identified that PKM2 was regulated by
AKT/mTORsignaling pathway in cell growth, survival, and
metabolism [30,33]. It was demonstrated that mTOR pathway
upregulated glycolysis in hepatocellular carcinoma [34]. However,
there is little information whether miRNA(s) is/are involved in
insulin-regulated mTOR/PKM2 pathway. We tested the effect of
insulin on the known and unknown miRNAs that target mTOR
and found out that miR-99a were regulated by insulin. In this
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study, we plan to determine 1) whether insulin regulates mTOR
through miR-99a; 2) whether insulin regulates glycolytic activities
via miR-99a/mTOR; 3) what is the downstream effectors of
mTOR for mediating insulin-induced glycolytic activities.
Materials and Methods
2.1 Reagents and Cell Lines
Antibodies against mTOR and PKM2 were purchased from
Cell Signaling Technology (Beverly, MA, USA). Antibody against
HIF-1a was purchased from Bioworld technology (Louis Park,
MN, USA) and BD Biosciences (Franklin Lakes, NJ, USA).
Antibodies against b-actin and GAPDH were purchased from
Sigma-Aldrich Inc. (St. Louis, MO, USA) and Kangchen Bio-tech
Inc. (Shanghai, China), respectively. Rapamycin was obtained
from Sigma-Aldrich and dissolved in DMSO. Insulin was obtained
from Biosharp (Korea) and dissolved in 50% Glycerol. Lipofecta-
mine and TRIzol reagent were provided by Life Technologies(-
Grand Island, NY, USA). MiR-99a mimics was provided by
GenePharma (Shanghai, China). HEK293, HepG2 cells were
obtained from American Type Culture Collection, HL7702
cellswere obtained from Cell bank of Chinese Academy of Science
(Shanghai, China). Cells were cultured according to the manu-
facturer’s instructions.
2.2 Cell Culture and Treatment
Human liver cells HL7702 and human liver carcinoma cell
HepG2 were cultured in cell medium and incubated in a
humidified incubator containing 5% CO2 at 37uC. HL7702 cells
were cultured in RPMI 1640 medium with 10% fetal bovine
serum (FBS), 100 units/ml penicillin, 100 mg/ml streptomycin,
whereasHepG2 cells were cultured in DMEM medium with 10%
FBS, 100 units/ml penicillin and 100 mg/ml streptomycin. For
insulin treatment, cells were seeded in 6-well plates or 24-well
plates and starved in low-glucose, serum-free medium for 18 hours
followed by treatment with insulin (200 nM) or basal medium for 6
hours. Before treated as above, some cells were transfected with
microRNA mimics (40 nM), siHIF-1a (40 nM) or negative control
oligomer for 24 hours or pretreated with rapamycin (5 nM) for 30
minutes.
2.3 Cell Transfection
Hsa-miR-99a or hsa-miR-SCR mimics were transfected into
HepG2 and HL7702 cells using lipofectamine reagent. Transfec-
tion complexes were prepared according to the manufacturer’s
instructions. The final concentrations of hsa-miR-99a or hsa-miR-
SCR mimics for the transfection were 40 nM. Similar method was
used to transfect siHIF-1a (40 nM) or siSCR into HepG2 cells as
above.
Figure 1. Insulin inhibited miR-99a expression, but induced glucose consumption and lactate production, and increased the
expression of mTOR, HIF-1a and PKM2 in HepG2 and HL7702 cells. HepG2 and HL7702 cells were starved in serum-free medium for 18 h,
and then treated with insulin (200 nM) for 6 h. (A) Cells were collected and subjected to miR-99a and U6 expression by qRT-PCR. Relative miR-99a
expression levels were normalized to U6. Data were presented by mean6SE (n = 3). **, indicates significant decrease compared to the cells without
insulin treatment (p,0.01). (B) The supernatant of cultured medium was collected and subjected to glucose assay of cells treated by insulin. Data
were presented by mean6SE (n = 3). * and **, indicate significant increase compared to the cells without insulin treatment (p,0.05 and p,0.01). (C)
The supernatant of cultured medium was collected and subjected to lactate assay. Data were presented by mean6SE (n = 3). *, indicates significant
increase compared to the cells without insulin treatment (p,0.05). (D) Cell pellets were collected and subjected to immunoblotting analysis of mTOR,
HIF-1a, PKM2 and GAPDH. (E) The density of protein levels of above was quantified by ImageJ software and normalized to the level of GAPDH. Data
were presented by mean6SE (n = 3). * and **, indicate significant increase compared to the cells without insulin treatment (p,0.05 and p,0.01).
doi:10.1371/journal.pone.0064924.g001
MiR-99a in Insulin-Promoted PKM2 Pathway
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2.4 RNA Isolation and Quantitative Real-time PCR
Total RNAs were extracted from cells using TRIzol reagent.
Stem-loop reverse transcriptase (RT) was carried out using
Primescript RT Regent Kit (Takara, Dalian, China) according
to the manufacturer’s instruction. The sequences of the RT
primers were as following: miR-99a-RT, 59-
CGTTGGTTGTCCCATAGACTCACAAGATC-39; U6-RT,
59-TGGTGTCGTGGAGTCG-39. Real-time PCR was per-
formed using SYBR Premix DimerEraser (Takara, Dalian, China)
on a 7900 HT system, and RNA input was normalized to the level
of human U6 snRNA. The qPCR primers were as following: miR-
99a primers: sense: 59-GGCAAACCCGTAGATCCGA-39; anti-
sense: 59-TCCGTTGGTTGTCCCATAGACT-39. U6 snRNA
primers: Sense: 59-CTCGCTTCGGCAGCACA-39; anti-sense:
59-AACGCTTCACGAATTTGCGT-39. The relative expressions
of miR-99a were normalized to the levels of U6 and analyzed via
the comparative cycle threshold method (22DDCT).
2.5 Protein Extraction and Immunoblotting Analysis
Cells with specific treatments were lysed in radioimmunopre-
cipitation assay (RIPA) buffer (100 mMTris, pH 7.4, 150
mMNaCl, 5 mM EDTA, 1% Triton X-100, 1% deoxycholate
acid, 0.1% SDS) supplemented with protease inhibitors (2
mMphenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate,
2 mM DTT, 2 mMleupeptin, 2 mMpepstatin). The homogenates
were centrifugated at 12,000 rpm for 15 min at 4uC, and the
supernatants were collected and stored at 280uC. Protein
concentrations were measured by BCA assay. SDS-polyacryl-
Figure 2. Insulin induced mTOR expression, glucose consumption and lactate production via miR-99a. (A) The luciferase reporters
containing the wild type and mutant 39-UTR of mTOR at predicted miR-99a binding site were constructed and verified by sequencing. HEK-293 cells
were transfected with wild type or mutant reporter plasmid, scrambled control miRNA (miR-SCR) or miR-99a precursor, and pRL-TK plasmid, and the
relative luciferase activity was calculated as the ratio of firefly/renilla activities and normalized to that of the control. Data were presented by
mean6SE (n = 3). **, indicates significant decrease compared to the control (p,0.01). (B) Cells were transfected with miR-99a or miR-SCR at 40 nM.
After 72 h, the expression of mTOR and GAPDH was determined by immunoblotting (up panel). Relative quantitative levels of mTOR were measured
as above (bottom panel). * and **, indicate significant decrease compared to the miR-SCR group (p,0.05 and p,0.01). (C) HepG2 and HL7702 cells
were transfected as above, then starved and treated with or without insulin. Cell pellets were collected and the relative density of mTOR expression
was determined. The data were analyzed by ANOVA. *, indicates significant increase compared to the control without insulin treatment (p,0.05); #
and ##, indicate significant decrease compared to miR-SCR and insulin treatment (p,0.05 and p,0.01). The glucose consumption (D) and lactate
production (E) were tested in supernatant of treated cells as above. * and **, indicate significant increase compared to the control without insulin
treatment (p,0.05 and p,0.01); ##, indicates significant decrease compared to miR-SCR and insulin treatment (p,0.01).
doi:10.1371/journal.pone.0064924.g002
MiR-99a in Insulin-Promoted PKM2 Pathway
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amide gel electrophoresis (SDS-PAGE) was used to separate
protein extracts and then the gel was transferred to nitrocellulose
membranes. Membranes were blocked with 5% nonfat dry milk in
16 PBS containing 0.05% Tween-20 for 2 hours. The protein
bands were incubated with antibodies against mTOR,
PKM2,HIF-1a, GAPDH or b-actin and then secondary antibody
conjugated to horseradish peroxidase. The reaction signal was
detected with ECL Detection System (Thermo Scientific, MA,
USA).
2.6 Metabolism Assays
HepG2 and HL7702 cells were seeded into 24-well plate with
200 ml media each well. To determine the levels of glucose and
lactate in HepG2 and HL7702 cells, the supernatants of cell
culture media were collected and assayed for glucose and lactate
levels by using glucose assay kit and lactate assay kit (BioVision,
San Francisco, USA) according to the manufacturer’s instructions.
The values at different time periods were analyzed by the OD
values. Glucose consumption and lactate production were
calculated based on the standard curve, and normalized to the
cell number.
2.7 Vector Construction and Luciferase Assay
The mTOR 39-UTR sequence was amplified from human
cDNAs by PCR using the following primers: mTOR forward
primer, 59-GCGAGCTCCTTTAGAAATACGGGTTTT-
GACTTA-39; mTOR reverse primer, 59-GCAAGCTTGCC-
GAGGCTGCCAGCGATCTGAATA-39. For the mTOR muta-
genesis, the sequences complementary to the binding site of miR-
99a in the 39-UTR (UACGGGU) was replaced by AUGCCCA,
respectively [35]. The wildtype and mutated 39-UTR regions of
mTOR were cloned into pMIR-REPORT miRNA reporter
vector using the Sacl and HindIII sites. These constructs were
validated by DNA sequencing.
Figure 3. Overexpression of miR-99a or rapamycin treatment inhibited insulin-induced PKM2 and HIF-1a expression, and glucose
consumption and lactate production. (A)HepG2 and HL7702 cells were transfected with miR-99a and miR-SCR, and treated as in Fig. 2. The
expression levels of HIF-1a, PKM2 and b-actin were analyzed by immunoblotting. (B) Relative densities were determined as above and normalized to
b-actin expression level. Data were presented by mean6SE (n = 3). The data were analyzed by ANOVA. * and **, indicate significant decrease
compared to the control (p,0.05 and p,0.01); # and ##, indicate significant decrease compared to miR-SCR and insulin treatment (p,0.05 and
p,0.01). (C) Cells were pretreated with rapamycin (5 nM) for 30 min followed by insulin treatment for 6 h. The protein levels of mTOR, HIF-1a,
PKM2and b-actin were detected by immunoblotting. (D) Relative densities of protein expression above. The data were analyzed by ANOVA, **
indicates significant decrease compared to the control (p,0.01); # and ##, indicate significant decrease compared to DMSO and insulin treatment
(p,0.05 and p,0.01). (E) Glucose assay and (F) Lactate assay of cells treated as in Fig. 2C. *, indicates significant decrease compared to the control
(p,0.05); # and ##, indicate significant decrease compared to DMSO and insulin treatment (p,0.05 and p,0.01).
doi:10.1371/journal.pone.0064924.g003
MiR-99a in Insulin-Promoted PKM2 Pathway
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HEK-293 cells were seeded into a 24-well plate. After cultured
for 24 hours, cells were co-transfected with wild-type or mutant
mTOR 39-UTR reporter plasmid and pRL-TK plasmid (as
control), or transfected with pre-miR-99a and miR-scrambled
control precursors (miR-SCR). Luciferase assays were performed
48 hours after tranfection using the Dual Luciferase Reporter
Assay System (Promega, WI, USA).
2.8 Statistical Analysis
In this study, each value was obtained from at least three
independent experiments and presented as means 6 SE. Student’s
unpaired t test. The data were analyzed by ANOVA for groups
with 3 and more treatments, and by Student’s unpaired t test for
groups with two treatments The values were considered signifi-
cantly different between groups when P,0.05.
Results
Insulin Inhibited miR-99a Expression, but Induced
Glucose Consumption and Lactate Production, and
Increased the Expression Levels of mTOR,
Phosphorylated mTOR (p-mTOR), HIF-1a and PKM2 in
HepG2 and HL7702 Cells
Recent studies have shown that mTOR is involved in glucose
metabolism [36,37,38,39]. Lactate, a product from glucose
metabolism, is produced from pyruvate conversion. In order to
test whether certain miRNA(s) could affect insulin-mediated
glucose metabolism, we tested the potential miRNAs that target
mTOR and interestingly found that miR-99a was downregulated
by 2-fold in both HepG2 and HL7702 cells after insulin treatment
(Fig. 1A). Meanwhile, insulin induced glucose consumption and
lactate production to more than 1.5-fold in both cells (Figs. 1B and
1C). mTORis an important regulator in insulin-induced activation
of S6 and 4EBP1 signals [40]. Here we showed that insulin
treatment increased mTOR expression at total and phosphory-
lated protein levels (Figs. 1D, 1E, and S1). Consistent with
previous studies showing that HIF-1 is one of the downstream
molecules regulated by mTOR/p70S6K1, insulin treatment
stimulated HIF-1a expression. PKM2, a critical enzyme for
aerobic glycolysis and tumor growth [14,30], was also up-
regulated by insulin treatment (Figs. 1D and 1E). These results
suggest that insulin may down-regulate miR-99a, up-regulate
mTOR, HIF-1a, PKM2 expression and promoteglycolytic activ-
ities.
Figure 4. siHIF-1a inhibited HIF-1a and PKM2 expression and insulin-induced glucose consumption. HepG2 cells were transfected with
siHIF-1a (40 nM) and siSCR for 24 h. Protein levels of HIF-1a (A) and PKM2 (B) were analyzed by immunoblotting. Histogram represents the levels of
HIF-1a and PKM2 normalized to b-actin (mean6SEM; n = 3). * and **, indicate significant decrease compared to the control (p,0.05 and p,0.01). (C)
HepG2 cells were transfected with siHIF-1a and siSCR for 24 h, then starved for 18 h followed by insulin treatment for 6 h. Glucose assay of cells was
tested as above. The data were analyzed by ANOVA. **, indicates significant increase compared to the control without insulin treatment (p,0.01); #,
indicates significant decrease compared to siSCR and insulin treatment (p,0.05).
doi:10.1371/journal.pone.0064924.g004
Figure 5. Outline of pathway in insulin-induced glucose
consumption. Insulin inhibits the expression of miR-99a, then induces
miR-99a direct target mTOR which in turn increases PKM2 and HIF-1a
expression for regulating glucose consumption. mTOR inhibitor
Rapamycin can inhibit this pathway.
doi:10.1371/journal.pone.0064924.g005
MiR-99a in Insulin-Promoted PKM2 Pathway
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Insulin Induced mTOR Expression Levels, Glucose
Consumption and Lactate Production via miR-99a
We found a negative correlation between miR-99a and mTOR
expression levels under the insulin treatment. We hypothesize that
insulin regulates glucose consumption through mTOR/PKM2
pathway via miR-99a. To determine whether mTOR is a direct
target of miR-99a, the 39-UTR region of mTOR was cloned into
pMIR-REPORT miRNA reporter vector. Consistent with a
recent study showing that miR-99a directly targets and regulates
mTOR in childhood adrenocortical tumors [41], we found that
forced expression of miR-99a suppressed luciferase activity of the
wild type, but not the mutant mTOR reporter (Fig. 2A) and
mTOR expression at protein level (Fig. 2B). To further study
whether insulin stimulates glucose consumption via regulating
miR-99a and mTOR, HepG2 and HL7702 cells were transfected
with pre-miR-99a and negative control of miRNA precursor
(miR-SCR). As we expected, miR-99a overexpression inhibited
insulin-induced total mTOR and p-mTOR expression levels
(Figs. 2C and S1). In agreement with the mTOR suppression,
miR-99a overexpression also inhibited insulin-induced glucose
consumption (Fig. 2D) and lactate production by 30–40% and 30–
35%, respectively in HepG2 and HL7702 cells (Fig. 2E). These
results indicate that miR-99a is an important regulator in insulin-
regulated glycolytic activities through directly targeting mTOR.
Overexpression of miR-99a or Rapamycin Treatment
Inhibited Insulin-induced PKM2 and HIF-1a Expression,
and Glucose Consumption and Lactate Production
Recent studies have demonstrated that PKM2 can be regulated
by mTOR pathway [30,31]. In order to study whether mTOR is
required for PKM2 in regulating insulin-inducing glucose
consumption, we found that inhibition of mTOR by miR-99a
overexpression significantly suppressed the downstream molecules
HIF-1a and PKM2 expression under the insulin treatment
(Figs. 3A and 3B). Similarly, rapamycin, the mTOR inhibitor,
also strongly attenuated insulin-induced HIF-1a and PKM2
expression in both HepG2 and HL7702 cells (Figs. 3C and 3D).
Rapamycin also decreased insulin-induced glucose consumption
and lactate production in these cells (Figs. 3E and 3F). These
results demonstrate that insulin induces glucose consumption and
lactate production through mTOR/PKM2 pathway, which can
be blocked by miR-99a or mTOR inhibitor.
Knockdown of HIF-1a Inhibited PKM2 Expression and
Insulin-induced Glucose Consumption
PKM2 regulates glucose metabolism by functioning as a PHD3-
stimulated coactivator for hypoxia-inducible factor 1 in cancer
cells [29,42]. A recent study has demonstrated that mTOR up-
regulated of PKM2 expression via hypoxia-inducible factor 1a
(HIF-1a)-mediated transcription activation [30]. To determine
whether HIF-1a is required for insulin-regulated glucose con-
sumption through PKM2, we knockdown HIF-1a by siRNA
approach. Transfection with siHIF-1a in HepG2 decreased HIF-
1a protein expression to 40% and reduced PKM2 expression by
40% when compared to the scrambled control (Figs. 4A–C). In
addition, HIF-1a Knockdown almost abolished insulin-induced
glucose consumption in HepG2 cells (Fig. 4C), suggesting that
HIF-1a is necessary for PKM2 in insulin-induced glucose
consumption.
Discussion
mTOR pathway plays a central role in regulating protein
synthesis, ribosomal protein translation, and cap-dependent
translation [16,43,44,45,46,47]. mTOR is recently demonstrated
to regulate aerobic glycolysis in cancer cells and promote tumor
growth through up-regulation of PKM2 [30,31]. PKM2 is a
ubiquitous prototype enzyme present in embryonic tissues and
adult dividing/tumor cells [48]. PKM2 play a critical role in
tumor development through its two functions: acting as glycolytic
enzyme and protein-kinase-phosphorylating histone [25]. In
addition to its primary function to catabolize glucose, PKM2 is
the last and the main rate-limiting enzyme in glycolytic pathway
[26]. PKM2 is a multifunctional protein and is associated with
metabolic regulation, cellular growth, apoptosis and immunolog-
ical responses [48,49]. Our study demonstrated that insulin
significantly inhibited miR-99a expression and induced mTOR
expression, while forced expression of miR-99a was sufficient to
inhibit insulin-induced mTOR expression. In addition, miR-99a
enhanced the efficacy of photofrin based photodynamic in human
glioblastoma [50]. In esophageal squamous cell carcinoma, miR-
99a was significantly decreased, and forced expression of miR-99a
inhibited cell proliferation by inducing apoptosis [51]. Up to now,
it is unclear about the role of miR-99a in insulin-regulated
glycolysis.
This study provides a link between insulin and mTOR protein
expression regulated by miRNA. In this study, we also showed that
insulin induced PKM2 expression and glucose consumption and
lactate production, which was regulated by miR-99a/mTOR.
This result suggests that PKM2 is a downstream molecule of miR-
99a via targeting mTOR, and is involved in insulin-induced
glucose metabolism.
Hypoxia-induced factor 1 (HIF-1) is a transcriptional factor
consisting of HIF-1a and HIF-1b subunits. HIF-1a mediates
essential homeostatic responses to cellular and systemic hypoxia by
activating transcription of multiple genes including those encoding
erythropoietin, glycolytic enzymes and vascular endothelial growth
factor (VEGF) [52,53]. HIF-1 is known to be involved in insulin
signaling. For example, insulin-like growth factor-1 (IGF-1)
promotes cell survival, proliferation and angiogenesis via inducing
HIF-1a expression [54,55]. Our previous studies have demon-
strated HIF-1a is regulated via PI3K/AKT signal pathway in
cancer cells [39,56]. In this study, we showed that HIF-1a is
repressed by miR-99a overexpression through inhibiting mTOR
and it is involved in glucose consumption in response to insulin
treatment. PKM2 are found to regulate glucose metabolism by
coactivating with HIF-1a [29,42]. A recent study has demonstrat-
ed that mTOR up-regulation of PKM2 expression is through HIF-
1a-mediated transcription activation and c-Myc-heterogeneous
nuclear ribonucleoproteins-dependent regulation of PKM2 gene
splicing [30]. In the present study, we found that miR-99a/
mTOR/PKM2 pathway is involved in insulin-induced glucose
metabolism, and mTOR and HIF-1a are necessary for insulin-
induced PKM2 expression and glucose consumption. The results,
for the first time, reveal the important role of miR-99a in glycolysis
under insulin treatment.
In summary, our study demonstrates that insulin regulates cell
glycolysis via inhibition of miR-99a expression in liver cells, and
miR-99a/mTOR/HIF-1 is important in insulin-regulated PKM2
expression and glucose consumption (Fig. 5). This finding provides
a novel understanding to the molecular mechanism for biological
function of insulin in cells.
MiR-99a in Insulin-Promoted PKM2 Pathway
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Supporting Information
Figure S1 Insulin induced phosphorylated mTOR (p-
mTOR) expression levels, while overexpression of miR-
99a and rapamycin treatment inhibited insulin-induced
p-mTOR levels. (A) HepG2 and HL7702 cells were starved in
serum-free medium for 18 h, then treated with insulin (200 nM)
for 6 h. Cells were collected and subjected to immunoblotting
using antibodies against p-mTOR and GAPDH. (B) The cells
were transfected with miR-99a (+) or miR-SCR (–) precursor, and
cultured for 60 hours, then treated with or without insulin as
above. The expression levels of p-mTOR and GAPDH were
analyzed by immunoblotting. (C) Cells were pretreated with
rapamycin (5 nM) for 30 min, followed by insulin treatment for
6 h. The protein levels of p-mTOR and GAPDH were detected by
immunoblotting.
(PPTX)
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